RCM
OACC

Radcliffe Capital Management’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Radcliffe Capital Management’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.06M Buy
382,445
+5,380
+1% +$57.3K 0.3% 125
2025
Q4 		$3.99M Buy
377,065
+151,403
+67% +$1.6M 0.22% 121
2025
Q3 		$2.37M Buy
225,662
+143,749
+175% +$1.5M 0.15% 127
2025
Q2 		$856K Buy
+81,913
New +$850K 0.07% 106

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Radcliffe Capital Management's OACC Position: Q1 2026 in Review

Radcliffe Capital Management increased its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 1.4% in Q1 2026, buying an estimated $57.3K and bringing the position to 382,445 shares worth $4.06M. The position accounts for 0.3% of the portfolio, ranked #125.

Radcliffe Capital Management first reported a position in OACC in Q2 2025 and has held it in 4 quarters since. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • Radcliffe Capital Management held 382,445 shares of Oaktree Acquisition Corp III Life Sciences worth $4.06M as of Q1 2026.
  • Radcliffe Capital Management bought 5,380 Oaktree Acquisition Corp III Life Sciences shares in Q1 2026, an estimated $57.3K.
  • Oaktree Acquisition Corp III Life Sciences made up 0.3% of Radcliffe Capital Management's portfolio in Q1 2026, its #125 holding.
  • Radcliffe Capital Management first reported a position in Oaktree Acquisition Corp III Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Radcliffe Capital Management's 13F filing for Q1 2026, filed 15 May 2026.